A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of BIV201 (terlipressin diacetate) as a continuous infusion
in addition to standard of care (diuretics and therapeutic paracentesis) for reduction of
ascites and complications in adult patients with refractory ascites secondary to
decompensated cirrhosis